Literature DB >> 19662925

Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions.

Sunil K Aggarwal1, Gregory T Carter, Mark D Sullivan, Craig ZumBrunnen, Richard Morrill, Jonathan D Mayer.   

Abstract

Cannabis (marijuana) has been used for medicinal purposes for millennia, said to be first noted by the Chinese in c. 2737 BCE. Medicinal cannabis arrived in the United States much later, burdened with a remarkably checkered, yet colorful, history. Despite early robust use, after the advent of opioids and aspirin, medicinal cannabis use faded. Cannabis was criminalized in the United States in 1937, against the advice of the American Medical Association submitted on record to Congress. The past few decades have seen renewed interest in medicinal cannabis, with the National Institutes of Health, the Institute of Medicine, and the American College of Physicians, all issuing statements of support for further research and development. The recently discovered endocannabinoid system has greatly increased our understanding of the actions of exogenous cannabis. Endocannabinoids appear to control pain, muscle tone, mood state, appetite, and inflammation, among other effects. Cannabis contains more than 100 different cannabinoids and has the capacity for analgesia through neuromodulation in ascending and descending pain pathways, neuroprotection, and anti-inflammatory mechanisms. This article reviews the current and emerging research on the physiological mechanisms of cannabinoids and their applications in managing chronic pain, muscle spasticity, cachexia, and other debilitating problems.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19662925     DOI: 10.5055/jom.2009.0016

Source DB:  PubMed          Journal:  J Opioid Manag        ISSN: 1551-7489


  40 in total

1.  Survey results of pain treatments in adults with cerebral palsy.

Authors:  Adam T Hirsh; Anna L Kratz; Joyce M Engel; Mark P Jensen
Journal:  Am J Phys Med Rehabil       Date:  2011-03       Impact factor: 2.159

Review 2.  Blurred boundaries: the therapeutics and politics of medical marijuana.

Authors:  J Michael Bostwick
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

Review 3.  Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system?

Authors:  Rebecca M Craft; Julie A Marusich; Jenny L Wiley
Journal:  Life Sci       Date:  2012-06-20       Impact factor: 5.037

Review 4.  State of the art treatments for cannabis dependence.

Authors:  Itai Danovitch; David A Gorelick
Journal:  Psychiatr Clin North Am       Date:  2012-04-10

Review 5.  Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

Authors:  Simone Tambaro; Marco Bortolato
Journal:  Recent Pat CNS Drug Discov       Date:  2012-04-01

6.  Suppression of CpG-ODN-mediated IFNα and TNFα response in human plasmacytoid dendritic cells (pDC) by cannabinoid receptor 2 (CB2)-specific agonists.

Authors:  Joseph E Henriquez; Robert B Crawford; Norbert E Kaminski
Journal:  Toxicol Appl Pharmacol       Date:  2019-02-23       Impact factor: 4.219

7.  Pharmacy Student Knowledge, Confidence and Attitudes Toward Medical Cannabis and Curricular Coverage.

Authors:  Frank J Caligiuri; Erin E Ulrich; Kelli Jo Welter
Journal:  Am J Pharm Educ       Date:  2018-06       Impact factor: 2.047

Review 8.  Amygdala FAAH and anandamide: mediating protection and recovery from stress.

Authors:  Ozge Gunduz-Cinar; Matthew N Hill; Bruce S McEwen; Andrew Holmes
Journal:  Trends Pharmacol Sci       Date:  2013-10-25       Impact factor: 14.819

9.  Evaluation of sex differences in cannabinoid dependence.

Authors:  Julie A Marusich; Timothy W Lefever; Kateland R Antonazzo; Rebecca M Craft; Jenny L Wiley
Journal:  Drug Alcohol Depend       Date:  2014-02-12       Impact factor: 4.492

10.  Effect of the CB1 cannabinoid agonist WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference in mice.

Authors:  Carmen Manzanedo; Marta Rodríguez-Arias; Manuel Daza-Losada; Concepción Maldonado; María A Aguilar; José Miñarro
Journal:  Behav Brain Funct       Date:  2010-03-22       Impact factor: 3.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.